kpl-716
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 6, 2019 (NCT03816891)
Timeline
Indications
Mechanism of action
PECAM1 inhibitor
Oncostatin-M-specific receptor subunit beta inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594341 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06693908 | Phase 1 | Feb 21, 2025 | Genentech, Roche |
| NCT06137183 | Phase 2 | Jan 15, 2024 | Genentech |
| NCT05785624 | Phase 2 | May 26, 2023 | Genentech, Roche |
| NCT03858634 | Phase 2 | May 29, 2019 | Kiniksa Pharmaceuticals, Ltd. |
| NCT03816891 | Phase 2 | Mar 6, 2019 | Kiniksa Pharmaceuticals, Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 3 | 3 | 2 | 2023 |
| Kiniksa Pharmaceuticals, Ltd. | For profit | 2 | 2 | 1 | 2019 |
| Roche | For profit | 2 | 0 | 2 | 2023 |
3 organizations
Page 1 / 1